

Genomic analysis of ST88 Community-Acquired methicillin resistant *Staphylococcus aureus* in Ghana

Grace Kpeli ^{Corresp., 1,2,3}, Andrew H Buultjens ⁴, Stefano Giuliani ⁴, Evelyn Owusu-Mireku ¹, Samuel Y Aboagye ¹, Sarah L Baines ⁴, Torsten Seemann ^{4,5}, Dieter Bulach ^{4,5}, Anders Gonçalves da Silva ⁴, Ian R Monk ⁴, Benjamin P Howden ^{4,6,7}, Gerd Pluschke ^{2,3}, Dorothy Yeboah-Manu ¹, Timothy Stinear ^{Corresp., 4}

¹ Bacteriology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana

² Molecular Parasitology and Immunology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland

³ University of Basel, Basel, Switzerland

⁴ Doherty Applied Microbial Genomics, Department of Microbiology and Immunology, Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Australia

⁵ University of Melbourne, Victorian Life Sciences Computation Initiative (VLSCI), Melbourne, Australia

⁶ Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, Doherty Institute for Infection & Immunity, University of Melbourne, Melbourne, Australia

⁷ Infectious Diseases Department, Austin Health, Heidelberg, Australia

Corresponding Authors: Grace Kpeli, Timothy Stinear

Email address: gkpel@noguchi.ug.edu.gh, tstinear@unimelb.edu.au

Background. The emergence and evolution of community-acquired methicillin resistant *Staphylococcus aureus* (CA-MRSA) strains in Africa is poorly understood. However, one particular MRSA lineage called ST88, appears to be rapidly establishing itself as an "African" CA-MRSA clone. In this study, we employed whole genome sequencing to provide more information on the genetic background of ST88 CA-MRSA isolates from Ghana and to describe in detail ST88 CA-MRSA isolates in comparison with other MRSA lineages worldwide. **Methods.** We first established a complete ST88 reference genome (AUS0325) using PacBio SMRT sequencing. We then used comparative genomics to assess relatedness among 17 ST88 CA-MRSA isolates recovered from patients attending Buruli ulcer treatment centers in Ghana, three non-African ST88s and 15 other MRSA lineages. **Results.** We show that Ghanaian ST88 forms a discrete MRSA lineage (harbouring SCCmec-IV [2B]). Gene content analysis identified five distinct genomic regions enriched among ST88 isolates compared with the other *S. aureus* lineages. The Ghanaian ST88 isolates had only 658 core genome SNPs and there was no correlation between phylogeny and geography, suggesting the recent spread of this clone. The lineage was also resistant to multiple classes of antibiotics including β -lactams, tetracycline and chloramphenicol. **Discussion.** This study reveals that *S. aureus* ST88-IV is a recently emerging and rapidly spreading CA-MRSA clone in Ghana. The study highlights the capacity of small snapshot genomic studies to provide actionable public health information in resource limited settings. To our knowledge this is the first genomic assessment of the ST88 CA-MRSA

clone.

21 **Corresponding author:** Timothy Stinear (tstinear@unimelb.edu.au)

22

23

24 **Abstract**

25 **Background.** The emergence and evolution of community-acquired methicillin resistant
26 *Staphylococcus aureus* (CA-MRSA) strains in Africa is poorly understood. However, one
27 particular MRSA lineage called ST88, appears to be rapidly establishing itself as an ``African``
28 CA-MRSA clone. In this study, we employed whole genome sequencing to provide more
29 information on the genetic background of ST88 CA-MRSA isolates from Ghana and to describe
30 in detail ST88 CA-MRSA isolates in comparison with other MRSA lineages worldwide.

31 **Methods.** We first established a complete ST88 reference genome (AUS0325) using PacBio
32 SMRT sequencing. We then used comparative genomics to assess relatedness among 17 ST88
33 CA-MRSA isolates recovered from patients attending Buruli ulcer treatment centers in Ghana,
34 three non-African ST88s and 15 other MRSA lineages.

35 **Results.** We show that Ghanaian ST88 forms a discrete MRSA lineage (harbouring SCC*mec*-IV
36 [2B]). Gene content analysis identified five distinct genomic regions enriched among ST88
37 isolates compared with the other *S. aureus* lineages. The Ghanaian ST88 isolates had only 658
38 core genome SNPs and there was no correlation between phylogeny and geography, suggesting
39 the recent spread of this clone. The lineage was also resistant to multiple classes of antibiotics
40 including β -lactams, tetracycline and chloramphenicol.

41 **Discussion.** This study reveals that *S. aureus* ST88-IV is a recently emerging and rapidly spreading CA-
42 MRSA clone in Ghana. The study highlights the capacity of small snapshot genomic studies to provide
43 actionable public health information in resource limited settings. To our knowledge this is the first
44 genomic assessment of the ST88 CA-MRSA clone.

45

46

47

48 Introduction

49 Since the 1990s, community acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA)
50 infections have been increasing worldwide (CDC, 2013; de Kraker, Davey & Grundmann, 2011).
51 CA-MRSA clones are known to be more virulent than hospital-acquired MRSA, with infections
52 linked to significant mortality and morbidity (Chambers, 2001; Chua et al., 2014; Chua et al.,
53 2011; Etienne, 2005; Kourbatova et al., 2005; Seybold et al., 2006). First reported in Australia
54 and the United States, CA-MRSA occurrence has been increasing, with epidemics due to clones
55 such as ST8 USA300 in the United States (Diekema et al., 2014), ST93 and ST1 in Australia
56 (Coombs et al., 2009), ST80 in Europe (Otter & French, 2010), ST59 in China and Taiwan
57 (Chen & Huang, 2014), ST772 in India (D'Souza, Rodrigues & Mehta, 2010; DeLeo et al., 2010;
58 Nadig et al., 2012; Shambat et al., 2012) and ST72 in South Korea (Kim et al., 2007). Other
59 identified CA-MRSA clones belong to ST30 (South West Pacific clone) (Williamson, Coombs &
60 Nimmo, 2014), ST45 (Berlin clone) (Witte et al., 1997), ST1 (USA400) (DeLeo et al., 2010) and
61 ST78 (Western Australian MRSA-2) (Williamson, Coombs & Nimmo, 2014). In Africa, the
62 distribution of MRSA clones in general is not well understood (Abdulgader et al., 2015). A
63 recent review on MRSA in Africa with data from 15 of the 54 countries identified community
64 clones of ST8-IV [2B] (USA300) and ST88-IV [2B] “West Australia MRSA-2 clone” in both
65 community and health care associated infections in seven countries and a “Brazilian/Hungarian
66 clone” ST239-III [3A] in hospital acquired infections in nine countries (Abdulgader et al., 2015).
67 The European ST80-IV [2B] clone was limited to Algeria, Egypt and Tunisia while clonal types
68 ST22-IV [2B], ST36-II [2A], and ST612-IV [2B] have only been reported so far in South Africa
69 (Abdulgader et al., 2015). Among the two CA-MRSA clones, the ST8IV [2B] clone is an
70 internationally disseminated clone recognized in every continent except Antarctica (David &

71 Daum, 2010). The ST88-IV [2B] CA-MRSA clone however is predominant in Sub-Saharan
72 Africa (West, Central and East Africa) with reported rates of 24.2-83.3% of all MRSA isolates
73 (Schaumburg et al., 2014). Studies from Angola (Conceicao et al., 2014), Cameroon (Breurec et
74 al., 2011), Gabon (Ateba Ngoa et al., 2012; Schaumburg et al., 2011), Ghana (Amissah et al.,
75 2015; Egyir et al., 2013; Egyir et al., 2014), Madagascar (Breurec et al., 2011), Niger (Breurec et
76 al., 2011), Nigeria (Ghebremedhin et al., 2009; Raji et al., 2013; Shittu et al., 2012) and Senegal
77 (Breurec et al., 2011) have identified it as a major circulating clone within both hospital and
78 community settings. It was also detected in children from West Africa who underwent surgery in
79 Switzerland but had been hospitalized in their home countries prior to surgical treatment (Blanc
80 et al., 2007). Globally, this clone has been identified in China (Yu et al., 2008) and Japan (Maeda
81 et al., 2012) in lower proportion (5.3-12.5%) than in Africa and sporadically in Belgium (Denis
82 et al., 2005), Portugal (Aires-de-Sousa, Correia & de Lencastre, 2008) and Sweden (Fang et al.,
83 2008).

84 Control of MRSA infections is assisted by a thorough knowledge of the epidemiology and
85 dissemination of specific clones. To this end we employed whole genome sequencing and
86 comparative genomics to describe in detail ST88 CA-MRSA isolates in comparison to other
87 MRSA lineages worldwide.

88

89

90 **Materials & Methods**

91 **Bacterial isolates and antibiogram analysis**

92 The 17 ST88 *S. aureus* isolates analyzed from Ghana are listed in Table 1 and comprised five
93 strains isolated in the Akwapim South District (Eastern Region) of Ghana with previously
94 published genome data (GenBank accession numbers LFNJ000000000, LFNI000000000,
95 LFNH000000000, LFMH000000000, LFMG000000000) (Amissah et al., 2015) and 12 isolates
96 recovered from wounds of 11 patients attending Buruli ulcer (BU) treatment centers in the Ga-
97 South and Ga-West municipalities (Greater Accra Region) of Ghana with two isolates from one
98 patient; one a PVL positive isolate and the other PVL negative. Patients were outpatients, nine of
99 whom had laboratory confirmed BU. Initial isolate identification was made using colony and
100 microscopic morphology, catalase and coagulase biochemical reactions and a Staphylase kit BD
101 BBL™ Staphyloslide Latex Test (Becton, Dickinson and Company) for further confirmation.
102 Antibiograms were determined using the Kirby Bauer disc diffusion method according to CLSI
103 guidelines (CLSI, 2014) and PCR targeting the *mecA* gene (Oliveira & de Lencastre, 2002) for
104 identification of MRSA. Ethical clearance was obtained from the institutional review board of
105 the Noguchi Memorial Institute for Medical Research (NMIMR) (Federal-wide Assurance
106 number FWA00001824). All study participants were well informed of the study objectives and
107 written informed consent was obtained either from the patient or from the guardian of the patient.

108

109 **DNA Extraction, Whole Genome Sequencing and Analysis**

110 Genomic DNA was extracted from isolates using the Qiagen DNeasy kit and protocol (Qiagen,
111 Hilden, Germany). DNA libraries were prepared using Nextera XT (Illumina, San Diego,
112 California, USA) and whole genome sequencing was performed using the Illumina MiSeq with 2
113 x 300 bp chemistry. Small Molecular Real Time sequencing was performed on the RS-II (Pacific

114 Biosciences) using P6-C4 chemistry, and reference genome assembly was performed as
115 described (Baines et al., 2016).

116

117 **Read mapping, variant calling and phylogenomic analysis**

118 The sequence reads were processed using *Nullarbor* (nullarbor.pl 0.6,
119 <https://github.com/tseemann/nullarbor>), a recently developed bioinformatics pipeline for public
120 health microbial genomics as described previously (Kwong et al., 2016). *S. aureus* ST88 raw
121 sequence reads with accession numbers ERS1354589-600 have been deposited in the European
122 Nucleotide Archive (ENA), Project PRJEB15428 (url -
123 <http://www.ebi.ac.uk/ena/data/view/PRJEB15428>). Ortholog clustering was performed using
124 Roary (Page et al., 2015) and was visualized with Fripan (<http://drpowell.github.io/FriPan/>).
125 Recombination within the core genome was inferred using ClonalFrameML v1.7 (Didelot &
126 Wilson, 2015) with the whole genome alignment generated by Nullarbor. Using FastTree v2.1.8
127 (Price, Dehal & Arkin, 2010), a ML tree was generated and used as a guide tree for
128 ClonalFrameML. Positions in the reference genome that were not present in at least one genome
129 (non-core) were omitted from the analysis using the “ignore_incomplete_sites true” option and
130 providing ClonalFrameML with a list of all non-core positions. Maximum likelihood trees were
131 constructed using a recombination free SNP alignment using FastTree. Bootstrap support was
132 derived from comparisons between the original tree against 1000 trees that were built upon
133 pseudo-alignments (sampled from the original alignment with replacement).

134

135 **Results and Discussion**

136 **ST88 complete reference genome**

137 A prerequisite for high-resolution comparative genomics by read-mapping is a high-quality,
138 complete reference genome, closely related to the bacterial population under investigation
139 (Kwong et al., 2016). There were no fully-assembled ST88 *S. aureus* genomes publicly
140 available, so to address this issue, we selected the methicillin-susceptible, penicillin-resistant
141 ST88 *S. aureus* isolate AUS0325. This clinical isolate was obtained in 2013 from a patient in
142 Melbourne, Australia who had a persistent infection of a prosthetic joint, and was part of a
143 separate, unpublished study. The AUS0325 genome comprised a 2,771,577 bp circular
144 chromosome with 32.9% GC content. There were no plasmids; the beta-lactamase operon (*bla*)
145 was carried by the Tn552 transposon and integrated into the chromosome. The overall
146 chromosome architecture of AUS0325 was like representative *S. aureus* genomes from other
147 community-associated lineages (ST1, ST8 and ST93) but with five distinct regions of difference,
148 discussed in more detail below (Fig. 1A). We took advantage of the PacBio data to define the
149 Sa_aus0325 methylome. Motif analysis and inspection of the AUS0325 annotation identified two
150 active type I restriction modification *hsdMS* loci. Protein alignment of the two *hsdS* alleles with
151 previously characterised *hsdS* proteins allowed the attribution of target recognition sequences to
152 either allele (Monk et al., 2015) (Table 2). The first *hsdS* recognized a motif not previously
153 described, while the second *hsdS* contained an identical sequence to the target recognition
154 domain-2 of CC30-2 and ST93-2, which recognises TCG (Table 2).

155

156 **ST88 population structure**

157 To understand the genomic diversity and evolutionary origin of the ST88 isolates, a core genome
158 phylogeny was inferred by mapping reads from the 17 ST88 isolates (Table 1, Fig. 1B), two
159 published ST88 MRSA genomes from Lebanon and USA and 15 other geographically and
160 genetically distinct *S. aureus* clones to AUS0325 (Table 3, Fig. 1B). To assess the clonal
161 ancestry, SNPs within inferred regions of recombination (71,862 clonal SNPs; 26,570
162 recombinogenic SNPs) (Fig. S1) were removed and a maximum likelihood phylogenomic tree
163 was established using the clonal core SNP alignment (71,862 SNPs). All 20 ST88 genomes
164 formed a discrete, closely related lineage, defined by only 1,759 core genome SNPs, compared
165 with 71,862 SNPs among all 35 *S. aureus* genomes (Fig. 1B, Fig. 2A). The global tree was
166 rooted using *Bacillus subtilis*_B4068 (GenBank ID: JXHK00000000) (Berendsen et al., 2016)
167 as an outgroup and this phylogeny indicated ST88 shares a most recent common ancestor
168 (MRCA) with ST72 (Fig. 1A).

169 Five distinct genomic regions were identified by ortholog comparisons, enriched among the
170 ST88 genomes compared to the 15 other diverse *S. aureus* genomes. These regions included
171 vSA α (GI-3, Fig. 1) that harboured 10 staphylococcal superantigen-like (*ssl*) genes, of which
172 four were uniquely present in the ST88 isolates. Upregulation of SSLs has been reported in some
173 CA-MRSA strains and may be involved in neutrophil and complement activation (Foster, 2005;
174 Voyich et al., 2005). GI-3 also harboured the first of the two functional type I restriction
175 modification *hsdMS* loci (see above, Table 2). GI-1 and GI-4 may be mobile integrative elements
176 of unknown function with the presence of putative integrases and four and 12 CDS respectively,
177 all encoding hypothetical proteins. GI-1 also harbours elements of a putative restriction
178 modification system (Fig. 1, Table S1). GI-2 contains 13 CDS, most of unknown function
179 although three CDS may encode membrane proteins (Fig. 1, Table S1). GI-5 had 14 CDS, that

180 included the second of the type I restriction modification *hsdMS* loci and seven CDS encoding
181 putative proteases (Table 2, Table S1).

182

183

184 **Evolution and molecular epidemiology of ST88 in Ghana**

185 To assess the evolutionary relationships among the ST88 genomes, a phylogenomic tree
186 comprised exclusively of ST88 genomes was established using clonal, core SNPs (1,759 clonal
187 SNPs; 207 recombinogenic SNPs) (Fig. S2, Fig. 2A). The tree was rooted using an ST93 genome
188 (Sa_JKD6159) as an outgroup. The phylogeny and the restricted genomic diversity (658 core
189 SNPs) suggests that the spread of ST88 MRSA in Ghana is a recent phenomenon, with isolates
190 from the United States, Australia and Lebanon ancestral to the spread of these isolates in Ghana.
191 Five specific clusters of CDS were also found to be exclusively present with the African ST88
192 genomes (Fig. 2C). These CDS were different to the five genomic regions identified in all ST88
193 relative to other *S. aureus* clones (Fig. 1B) suggesting that they were horizontally acquired by an
194 ST88 MRCA that has since spread in Ghana, (although a significantly larger sampling effort
195 would be required to confirm this hypothesis). These regions harbour CDS suggestive of
196 plasmid, phage and other mobile DNA elements (Table S2). We conducted a phylogeographic
197 analysis to formally assess the relationship between the Ghanaian ST88 phylogeny and the
198 specific geographic origin of the isolates, based on patient villages. However, there was no
199 correlation between geography and phylogeny, suggesting again that the spread of ST88 in
200 Ghana has been recent and rapid (Fig. 3).

201

202 **Phenotypic and genotypic antibiotic resistance**

203 All 17 Ghanaian ST88 isolates harboured a SCC*mec*-IV [2B] cassette, and displayed phenotypic
204 resistance to β -lactams, tetracycline, and chloramphenicol (Table 1). Isolates were variably
205 resistant to erythromycin, clindamycin, trimethoprim, amikacin and streptomycin (Table 1).
206 There was agreement between phenotypic and inferred genotypic resistance (Fig. 1B). For the
207 four genes (*blaZ*, *mecA*, *tetL*, *tetM*) detected in all 12 ST88 isolates from the Greater Accra
208 Region, resistance correlated with phenotypic resistance to all β -lactams and tetracyclines. Six
209 isolates showed phenotypic and genotypic resistance to chloramphenicol (Table 1, Fig. 1B). Five
210 of these isolates were from the same health center, however the time of isolation and the
211 geographic origins of the patients were different, suggesting that these isolates are spread across
212 the region and were not acquired from a common source.

213

214 **Conclusions**

215 The analysis presented here suggests that *S. aureus* ST88-IV is an emerging CA-MRSA clone in
216 Ghana. This has the potential to become a serious public health threat, with implications for the
217 treatment of *S. aureus* infections in Ghana, where there is no developed surveillance
218 infrastructure to monitor antibiotic resistance. The abuse and misuse of antibiotics by health care
219 givers and patients in Ghana is extensive (Kpeli et al., 2016). The development of resistance is
220 furthermore encouraged by the widespread availability of higher classes of antibiotics to lower
221 level health centers from regional medical stores, in addition to the unrestricted sale of these
222 medicines to over-the-counter medicine sellers by pharmaceutical wholesalers- even though
223 existing laws are supposed to limit the scope of these facilities to handle such medicines. Also

224 implicated and widely documented are the prescribing practices of clinicians; with over-reliance
225 on presumptive treatment and haphazardly prescribing antibiotics without recourse to due
226 laboratory investigation. CA-MRSA has undergone rapid evolution and expansion worldwide.
227 Because of its epidemic potential and limited treatment options, vigilance and antibiotic
228 stewardship programmes need to be put in place to prevent further spread.

229

230 **Acknowledgements**

231 We are grateful to the health care workers and patients at the Ga West and Ga South
232 Municipalities and to Miss Nana Ama Amissah for giving us access to genome data.

233

234 **References**

- 235 Abdulgader SM, Shittu AO, Nicol MP, and Kaba M. 2015. Molecular epidemiology of Methicillin-resistant
236 Staphylococcus aureus in Africa: a systematic review. *Front Microbiol* 6:348.
- 237 Aires-de-Sousa M, Correia B, and de Lencastre H. 2008. Changing patterns in frequency of recovery of
238 five methicillin-resistant Staphylococcus aureus clones in Portuguese hospitals: surveillance over
239 a 16-year period. *J Clin Microbiol* 46:2912-2917.
- 240 Amissah NA, Chlebowicz MA, Ablordey A, Sabat AJ, Tetteh CS, Prah I, van der Werf TS, Friedrich AW, van
241 Dijl JM, Rossen JW, and Stienstra Y. 2015. Molecular Characterization of Staphylococcus aureus
242 Isolates Transmitted between Patients with Buruli Ulcer. *PLoS Negl Trop Dis* 9:e0004049.
- 243 Ateba Ngoa U, Schaumburg F, Adegnikaa AA, Kosters K, Moller T, Fernandes JF, Alabi A, Issifou S, Becker
244 K, Grobusch MP, Kremsner PG, and Lell B. 2012. Epidemiology and population structure of
245 Staphylococcus aureus in various population groups from a rural and semi urban area in Gabon,
246 Central Africa. *Acta Trop* 124:42-47.
- 247 Baines SL, Howden BP, Heffernan H, Stinear TP, Carter GP, Seemann T, Kwong JC, Ritchie SR, and
248 Williamson DA. 2016. Rapid Emergence and Evolution of Staphylococcus aureus Clones
249 Harboring fusC-Containing Staphylococcal Cassette Chromosome Elements. *Antimicrob Agents*
250 *Chemother* 60:2359-2365.
- 251 Berendsen EM, Wells-Bennik MH, Krawczyk AO, de Jong A, van Heel A, Eijlander RT, and Kuipers OP.
252 2016. Draft genome sequences of 10 Bacillus subtilis strains that form spores with high or low
253 heat resistance. *Genome announcements* 4:e00124-00116.
- 254 Blanc DS, Petignat C, Wenger A, Kuhn G, Vallet Y, Fracheboud D, Trachsel S, Reymond M, Troillet N,
255 Siegrist HH, Ouevray S, Bes M, Etienne J, Bille J, Francioli P, and Zanetti G. 2007. Changing

- 256 molecular epidemiology of methicillin-resistant *Staphylococcus aureus* in a small geographic
257 area over an eight-year period. *J Clin Microbiol* 45:3729-3736.
- 258 Breurec S, Zriouil SB, Fall C, Boisier P, Brisse S, Djibo S, Etienne J, Fonkoua MC, Perrier-Gros-Claude JD,
259 Pouillot R, Ramarokoto CE, Randrianirina F, Tall A, Thiberge JM, Laurent F, and Garin B. 2011.
260 Epidemiology of methicillin-resistant *Staphylococcus aureus* lineages in five major African
261 towns: emergence and spread of atypical clones. *Clin Microbiol Infect* 17:160-165.
- 262 CDC. 2013. Antibiotic Resistance Threats in the United States, 2013. In: U.S. Department of Health and
263 Human Services CfDC, editor.
- 264 Chambers HF. 2001. The changing epidemiology of *Staphylococcus aureus*? *Emerg Infect Dis* 7:178-182.
- 265 Chen CJ, and Huang YC. 2014. New epidemiology of *Staphylococcus aureus* infection in Asia. *Clin*
266 *Microbiol Infect* 20:605-623.
- 267 Chua KY, Monk IR, Lin YH, Seemann T, Tuck KL, Porter JL, Stepnell J, Coombs GW, Davies JK, Stinear TP,
268 and Howden BP. 2014. Hyperexpression of alpha-hemolysin explains enhanced virulence of
269 sequence type 93 community-associated methicillin-resistant *Staphylococcus aureus*. *BMC*
270 *Microbiol* 14:31.
- 271 Chua KY, Seemann T, Harrison PF, Monagle S, Korman TM, Johnson PD, Coombs GW, Howden BO,
272 Davies JK, Howden BP, and Stinear TP. 2011. The dominant Australian community-acquired
273 methicillin-resistant *Staphylococcus aureus* clone ST93-IV [2B] is highly virulent and genetically
274 distinct. *PLoS One* 6:e25887.
- 275 CLSI. 2014. Performance standards for Antimicrobial Susceptibility Testing: Twenty fourth Informational
276 Supplement M100-S24. Wayne, PA, USA.
- 277 Conceicao T, Coelho C, Santos-Silva I, de Lencastre H, and Aires-de-Sousa M. 2014. Epidemiology of
278 methicillin-resistant and -susceptible *Staphylococcus aureus* in Luanda, Angola: first description
279 of the spread of the MRSA ST5-IVa clone in the African continent. *Microb Drug Resist* 20:441-
280 449.
- 281 Coombs GW, Nimmo GR, Pearson JC, Christiansen KJ, Bell JM, Collignon PJ, and McLaws ML. 2009.
282 Prevalence of MRSA strains among *Staphylococcus aureus* isolated from outpatients, 2006.
283 *Commun Dis Intell Q Rep* 33:10-20.
- 284 D'Souza N, Rodrigues C, and Mehta A. 2010. Molecular characterization of methicillin-resistant
285 *Staphylococcus aureus* with emergence of epidemic clones of sequence type (ST) 22 and ST 772
286 in Mumbai, India. *J Clin Microbiol* 48:1806-1811.
- 287 David MZ, and Daum RS. 2010. Community-associated methicillin-resistant *Staphylococcus aureus*:
288 epidemiology and clinical consequences of an emerging epidemic. *Clin Microbiol Rev* 23:616-
289 687.
- 290 de Kraker ME, Davey PG, and Grundmann H. 2011. Mortality and hospital stay associated with resistant
291 *Staphylococcus aureus* and *Escherichia coli* bacteremia: estimating the burden of antibiotic
292 resistance in Europe. *PLoS Med* 8:e1001104.
- 293 DeLeo FR, Otto M, Kreiswirth BN, and Chambers HF. 2010. Community-associated methicillin-resistant
294 *Staphylococcus aureus*. *Lancet* 375:1557-1568.
- 295 Denis O, Deplano A, De Beenhouwer H, Hallin M, Huysmans G, Garrino MG, Glupczynski Y, Malaviolle X,
296 Vergison A, and Struelens MJ. 2005. Polyclonal emergence and importation of community-
297 acquired methicillin-resistant *Staphylococcus aureus* strains harbouring Panton-Valentine
298 leucocidin genes in Belgium. *J Antimicrob Chemother* 56:1103-1106.
- 299 Didelot X, and Wilson DJ. 2015. ClonalFrameML: Efficient Inference of Recombination in Whole Bacterial
300 Genomes. *PLoS Comput Biol* 11:e1004041-e1004041.
- 301 Diekema DJ, Richter SS, Heilmann KP, Dohrn CL, Riahi F, Tendolkar S, McDanel JS, and Doern GV. 2014.
302 Continued emergence of USA300 methicillin-resistant *Staphylococcus aureus* in the United
303 States: results from a nationwide surveillance study. *Infect Control Hosp Epidemiol* 35:285-292.

- 304 Egyir B, Guardabassi L, Nielsen SS, Larsen J, Addo KK, Newman M, and Larsen AR. 2013. Prevalence of
305 nasal carriage and diversity of *Staphylococcus aureus* among inpatients and hospital staff at
306 Korle Bu Teaching Hospital, Ghana. *J Glob Antimicrob Resist* 1:189–193.
- 307 Egyir B, Guardabassi L, Sorum M, Nielsen SS, Kolekang A, Frimpong E, Addo KK, Newman MJ, and Larsen
308 AR. 2014. Molecular epidemiology and antimicrobial susceptibility of clinical *Staphylococcus*
309 *aureus* from healthcare institutions in Ghana. *PLoS One* 9:e89716.
- 310 Etienne J. 2005. Panton-Valentine leukocidin: a marker of severity for *Staphylococcus aureus* infection?
311 *Clin Infect Dis* 41:591-593.
- 312 Fang H, Hedin G, Li G, and Nord CE. 2008. Genetic diversity of community-associated methicillin-
313 resistant *Staphylococcus aureus* in southern Stockholm, 2000-2005. *Clin Microbiol Infect* 14:370-
314 376.
- 315 Foster TJ. 2005. Immune evasion by staphylococci. *Nat Rev Microbiol* 3:948-958.
- 316 Ghebremedhin B, Olugbosi MO, Raji AM, Layer F, Bakare RA, Konig B, and Konig W. 2009. Emergence of
317 a community-associated methicillin-resistant *Staphylococcus aureus* strain with a unique
318 resistance profile in Southwest Nigeria. *J Clin Microbiol* 47:2975-2980.
- 319 Kim ES, Song JS, Lee HJ, Choe PG, Park KH, Cho JH, Park WB, Kim SH, Bang JH, Kim DM, Park KU, Shin S,
320 Lee MS, Choi HJ, Kim NJ, Kim EC, Oh MD, Kim HB, and Choe KW. 2007. A survey of community-
321 associated methicillin-resistant *Staphylococcus aureus* in Korea. *J Antimicrob Chemother*
322 60:1108-1114.
- 323 Kourbatova EV, Halvosa JS, King MD, Ray SM, White N, and Blumberg HM. 2005. Emergence of
324 community-associated methicillin-resistant *Staphylococcus aureus* USA 300 clone as a cause of
325 health care-associated infections among patients with prosthetic joint infections. *Am J Infect*
326 *Control* 33:385-391.
- 327 Kpeli G, Darko Otchere I, Lamelas A, Buultjens AL, Bulach D, Baines SL, Seemann T, Giulieri S, Nakobu Z,
328 Aboagye SY, Owusu-Mireku E, Pluschke G, Stinear TP, and Yeboah-Manu D. 2016. Possible
329 healthcare-associated transmission as a cause of secondary infection and population structure
330 of *Staphylococcus aureus* isolates from two wound treatment centres in Ghana. *New Microbes*
331 *New Infect* 13:92-101.
- 332 Kwong JC, Mercoulia K, Tomita T, Easton M, Li HY, Bulach DM, Stinear TP, Seemann T, and Howden BP.
333 2016. Prospective Whole-Genome Sequencing Enhances National Surveillance of *Listeria*
334 *monocytogenes*. *J Clin Microbiol* 54:333-342.
- 335 Maeda T, Saga T, Miyazaki T, Kouyama Y, Harada S, Iwata M, Yoshizawa S, Kimura S, Ishii Y, Urita Y,
336 Sugimoto M, Yamaguchi K, and Tateda K. 2012. Genotyping of skin and soft tissue infection
337 (SSTI)-associated methicillin-resistant *Staphylococcus aureus* (MRSA) strains among outpatients
338 in a teaching hospital in Japan: application of a phage-open reading frame typing (POT) kit. *J*
339 *Infect Chemother* 18:906-914.
- 340 Monk IR, Tree JJ, Howden BP, Stinear TP, and Foster TJ. 2015. Complete Bypass of Restriction Systems
341 for Major *Staphylococcus aureus* Lineages. *MBio* 6:e00308-00315.
- 342 Nadig S, Velusamy N, Lalitha P, Kar S, Sharma S, and Arakere G. 2012. *Staphylococcus aureus* eye
343 infections in two Indian hospitals: emergence of ST772 as a major clone. *Clin Ophthalmol* 6:165-
344 173.
- 345 Oliveira DC, and de Lencastre H. 2002. Multiplex PCR strategy for rapid identification of structural types
346 and variants of the *mec* element in methicillin-resistant *Staphylococcus aureus*. *Antimicrob*
347 *Agents Chemother* 46:2155-2161.
- 348 Otter JA, and French GL. 2010. Molecular epidemiology of community-associated methicillin-resistant
349 *Staphylococcus aureus* in Europe. *Lancet Infect Dis* 10:227-239.
- 350 Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MT, Fookes M, Keane JA, and Parkhill J. 2015.
351 Roary: Rapid large-scale prokaryote pan genome analysis. *bioRxiv*:019315.

- 352 Price MN, Dehal PS, and Arkin AP. 2010. FastTree 2—approximately maximum-likelihood trees for large
353 alignments. *PLoS One* 5:e9490.
- 354 Raji A, Ojemhen O, Umejiburu U, Ogunleye A, Blanc DS, and Basset P. 2013. High genetic diversity of
355 *Staphylococcus aureus* in a tertiary care hospital in Southwest Nigeria. *Diagn Microbiol Infect Dis*
356 77:367-369.
- 357 Schaumburg F, Alabi AS, Peters G, and Becker K. 2014. New epidemiology of *Staphylococcus aureus*
358 infection in Africa. *Clin Microbiol Infect* 20:589-596.
- 359 Schaumburg F, Ngoa UA, Kusters K, Kock R, Adegnika AA, Kremsner PG, Lell B, Peters G, Mellmann A,
360 and Becker K. 2011. Virulence factors and genotypes of *Staphylococcus aureus* from infection
361 and carriage in Gabon. *Clin Microbiol Infect* 17:1507-1513.
- 362 Seybold U, Kourbatova EV, Johnson JG, Halvosa SJ, Wang YF, King MD, Ray SM, and Blumberg HM. 2006.
363 Emergence of community-associated methicillin-resistant *Staphylococcus aureus* USA300
364 genotype as a major cause of health care-associated blood stream infections. *Clin Infect Dis*
365 42:647-656.
- 366 Shambat S, Nadig S, Prabhakara S, Bes M, Etienne J, and Arakere G. 2012. Clonal complexes and
367 virulence factors of *Staphylococcus aureus* from several cities in India. *BMC Microbiol* 12:64.
- 368 Shittu A, Oyedara O, Abegunrin F, Okon K, Raji A, Taiwo S, Ogunsoola F, Onyedibe K, and Elisha G. 2012.
369 Characterization of methicillin-susceptible and -resistant staphylococci in the clinical setting: a
370 multicentre study in Nigeria. *BMC Infect Dis* 12:286.
- 371 Voyich JM, Braughton KR, Sturdevant DE, Whitney AR, Said-Salim B, Porcella SF, Long RD, Dorward DW,
372 Gardner DJ, Kreiswirth BN, Musser JM, and DeLeo FR. 2005. Insights into mechanisms used by
373 *Staphylococcus aureus* to avoid destruction by human neutrophils. *J Immunol* 175:3907-3919.
- 374 Williamson DA, Coombs GW, and Nimmo GR. 2014. *Staphylococcus aureus* 'Down Under': contemporary
375 epidemiology of *S. aureus* in Australia, New Zealand, and the South West Pacific. *Clin Microbiol*
376 *Infect* 20:597-604.
- 377 Witte W, Kresken M, Bräulke C, and Cuny C. 1997. Increasing incidence and widespread dissemination of
378 methicillin-resistant *Staphylococcus aureus* (MRSA) in hospitals in central Europe, with special
379 reference to German hospitals. *Clin Microbiol Infect* 3:414-422.
- 380 Yu F, Chen Z, Liu C, Zhang X, Lin X, Chi S, Zhou T, and Chen X. 2008. Prevalence of *Staphylococcus aureus*
381 carrying Panton-Valentine leukocidin genes among isolates from hospitalised patients in China.
382 *Clin Microbiol Infect* 14:381-384.

385

386

387

388

389

390

391

392

393

394

395

396

397

Table 1 (on next page)

S. aureus ST88 isolates tested in this study

1 **Table 1:** *S. aureus* ST88 isolates tested in this study

Isolate ID	Origin (Ghana)	Phenotypic resistance*	Genotype (<i>spa</i>, <i>agr</i>, PVL)	Reference
Sa_NOG-W02	Greater Accra Region	cld, tet, amp, ery, fox, ctx, chl, cro	t939, agr-3, PVL +	This study
Sa_NOG-W25	Greater Accra Region	gen, amk, cld, str, amp, tet, sxt, cfx, ctx, chl, cro	t448, agr-3, PVL -	This study
Sa_NOG-W11	Greater Accra Region	str, amk, gen, sxt, cfx, cld, fox, ctx, tet, chl, cro, amp, ery	t186, agr-3, PVL +	This study
Sa_NOG-W13	Greater Accra Region	gen, str, amk, ctx, tet, chl, cro, sxt, cfx, amp, cld, fox	07-12-12-118-13-13, agr-3, PVL +	This study
Sa_NOG-W01	Greater Accra Region	amk, cfx, tet, ctx, chl, cro, fox	t186, agr-3, PVL +	This study
Sa_NOG-W10	Greater Accra Region	sxt, ery, gen, str, amk, cld, amp, cfx, tet, fox, ctx, chl, cro	t186, agr-3, PVL -	This study
Sa_NOG-W07	Greater Accra Region	gen, str, amp, tet, sxt, cfx, chl, cro, ctx, fox, cld, ery,	t448, agr-3, PVL -	This study
Sa_NOG-W14	Greater Accra Region	gen, ery, sxt, amk, cld, str, tet, amp, cfx, ctx, chl, cro, fox,	t2649, agr-3, PVL +	This study
Sa_NOG-W04	Greater Accra Region	sxt, ery, gen, str, amk, amp, cfx, tet, fox, ctx,	07-12-21-17-13-13- 34-34-33-34-34, agr-3,	This study

		chl, cro	PVL -	
Sa_NOG-W06	Greater Accra Region	sxt, gen, amk, cld, amp, tet, cfx, fox, chl, cro	t786, agr-3, PVL -	This study
Sa_NOG-W24	Greater Accra Region	gen, sxt, amk, str, amp, tet, cfx, ctx, chl, cro, fox,	t786, agr-3, PVL +	This study
Sa_NOG-W05	Greater Accra Region	ery, amk, str, amp, cfx, tet, sxt, cld,	t186, agr-3, PVL -	This study
BU_G0701_t5	Eastern Region	fox, ben, oxa, tet, chl	t786, agr-3, PVL -	(Amisshah et al., 2015b)
BU_G0201_t8	Eastern Region	fox, ben, oxa, tet, chl	t786, agr-3, PVL -	(Amisshah et al., 2015b)
BU_G0202_t2	Eastern Region	fox, ben, oxa, tet, chl	t786, agr-3, PVL -	(Amisshah et al., 2015b)
BU_G1905_t3	Eastern Region	fox, ben, oxa, tet, chl	t786, agr-3, PVL -	(Amisshah et al., 2015b)
BU_W13_11	Eastern Region	fox, ben, oxa, tet, chl	t186, agr-3, PVL -	(Amisshah et al., 2015b)

2 **Notes:** *oxacillin=oxa, cefoxitin=fox, tetracycline=tet, chloramphenicol=chl, cefuroxime=cfx, erythromycin=ery,
3 clindamycin=cld, sulphamethazole-trimethoprim=sxt, amikacin=amk, streptomycin=str, ampicillin=amp,
4 cefotaxime=ctx, ceftriaxone=cro, gentamicin=gen, benzylpenicillin=ben, *spa*=*Staphylococcus aureus* Protein A,
5 *agr*=Accessory Gene regulator, PVL=Pantone Valentine Leukocidin toxin

6

7

8

Table 2 (on next page)

Sa_ aus0325 methylome analysis

1 **Table 2:** Sa_ aus0325 methylome analysis

HsdS (nucleotide position)	TRD1	N	TRD2
397,724 -> 399,280	ACC	5	RTGT
1,849,852 <- 1,851,408	GAG	6	TCG

2

Table 3 (on next page)

Comparator Reference Genomes

1

Table 3: Comparator Reference Genomes

Sequence type	Region/Country of origin	MSSA/MRSA	Reference Strain	Assembly/Accession number
ST8	USA/Canada	CA-MRSA	<i>Staphylococcus aureus</i> subsp. <i>aureus</i> USA 300 FPR 3757	NC_007793.1
ST 1	USA/Canada	CA-MRSA	<i>Staphylococcus aureus</i> subsp. <i>aureus</i> MW2	NC_003923.1
ST 80	Europe	CA-MRSA	<i>Staphylococcus aureus</i> 11819-97	NC_017351.1
ST45	Europe/ USA/Canada	CA-MRSA	<i>Staphylococcus aureus</i> subsp. <i>aureus</i> 300-169	GCA_000534855.1
ST 30	Europe/ Australia/Asia	CA-MRSA	<i>Staphylococcus aureus</i> subsp. <i>aureus</i> _S2397	GCA_000577595.1
ST 72	Asia	CA-MRSA	<i>Staphylococcus aureus</i> MRSA_CVM43477	GCA_000830555.1
ST 59	Asia	CA-MRSA	<i>Staphylococcus aureus</i> subsp. <i>aureus</i> M013	NC_016928.1
ST93	Australia	CA-MRSA	<i>Staphylococcus aureus</i> subsp. <i>aureus</i> JKD 6159	NC_017338.1
ST 250	England	HA-MRSA	<i>Staphylococcus aureus</i> subsp. <i>aureus</i> COL	NC_002951.2
ST254	Japan	MSSA	<i>Staphylococcus aureus</i> subsp. <i>aureus</i> Newman	NC_009641.1
ST1	United Kingdom	MSSA	<i>Staphylococcus aureus</i> subsp. <i>aureus</i> MSSA476	NC_002953.3
ST5	Ireland	MSSA	<i>Staphylococcus aureus</i> subsp. <i>aureus</i> ED98	NC_013450.1
ST5	Japan	MRSA	<i>Staphylococcus aureus</i> subsp. <i>aureus</i> N315	NC_002745.2
ST 239	Australia	MRSA	<i>Staphylococcus aureus</i> subsp. <i>aureus</i> JKD 6008	NC_017341.1

ST772	India	MRSA	<i>Staphylococcus aureus</i> subsp. <i>aureus</i> _ST772-MRSA	GC_000516935.1
ST 88	Lebanon	MRSA	HST-105	GCA_000564895.1
ST 88	United States	MSSA	<i>Staphylococcus aureus</i> subsp <i>aureus</i> _21343	GCA_000245595.2

2

Figure 2

High resolution ST88 phylogeny and accessory genome analysis

(A). Phylogeny inferred by read-mapping and variant identification among only ST88 genomes. Tree was produced using FastTree based on a pairwise alignment of 1,759 non-recombinogenic core genome SNPs among the 20 ST88 genomes. All major nodes in the tree (red circles) had greater than 70% bootstrap support (1000 replicates). (B) Accessory gene content variation among the 20 ST88 genomes as assessed by ortholog comparisons using Roary. (C) Distinct genomic islands (GI) identified in Ghanaian isolates.





Figure 3

Relationship between phylogeny of Ghanaian ST88 and their geographic origin

(A) Phylogeographic alignment of phylogeny against isolate origin geography performed with GenGIS software and (B) Monte-Carlo analysis following 1000 permutations of tree tips and geography of originating villages. The arrangement derived from the data was not significantly different to that which is expected by chance alone (p value >0.05), indicating a lack of geographical structure among the ST88 genomes.

A



B

